On Friday, Haemonetics Corporation (NYSE: HAE) announced its plan to acquire Vivasure Medical Limited, a company headquartered in Ireland, specializing in innovative vascular closure technologies. This strategic acquisition aims to fortify Haemonetics’ market presence within structural heart and endovascular procedural domains. These areas have recently experienced growing demand, notably in large-bore vascular access applications.
The terms of the transaction include an initial payment of approximately 100 million euros, equivalent to $117 million, with potential milestone-related payments reaching an additional 85 million euros. Vivasure’s flagship product, the PerQseal Elite system, will enhance Haemonetics’ existing interventional portfolio by providing an advanced solution for closing large-bore arterial and venous access sites, which are common in complex cardiovascular interventions.
The PerQseal Elite device features a proprietary bioabsorbable patch designed to seal access sites internally within the vessel. The device supports access sizes up to 26 French, utilizing a fully absorbable and sutureless mechanism. This design optimizes interventional workflow while aiming to minimize procedural complications, which is critical in sophisticated cardiovascular treatments.
Vivasure has positioned the PerQseal Elite system competitively in regulatory markets. In 2025, the company filed a Premarket Approval application with the U.S. Food and Drug Administration (FDA) specifically for the arterial variant of the device. In Europe, regulatory approval is already in place, with the CE Mark granted for both arterial and venous indications, allowing commercial distribution across European jurisdictions.
Clinical evaluations further support the device’s efficacy and safety profile. Results from the multicenter ELITE arterial study demonstrated a 30-day safety outcome with no major complications reported. The study also recorded immediate median times to hemostasis and noted the absence of a requirement for a pre-close technique, highlighting procedural efficiency and patient safety benefits.
Haemonetics disclosed that the upfront payment for the acquisition will be adjusted to account for Vivasure’s previous investments and outstanding loans. Furthermore, additional consideration is contingent upon achieving predefined sales growth targets and operational milestones, underlining performance-based aspects of the agreement.
Management from Haemonetics emphasized the strategic significance of the acquisition. Ken Crowley, Vice President and General Manager of Interventional Technologies, stated that the integration of Vivasure’s technology expands the company’s comprehensive suite of vascular closure devices. This expansion is intended to reinforce Haemonetics’ competitive standing in the growing market for large-bore vascular closure technologies, particularly within fast-expanding categories such as structural heart and endovascular procedures.
Financially, Haemonetics is positioned to fund this acquisition through its current liquidity, reported to be $296.4 million in cash on hand as of September 27, 2025. This capital availability aligns with the company’s strategic objective to scale differentiated technologies in robustly growing segments of cardiovascular intervention.
Looking forward, Haemonetics plans to release its third-quarter fiscal 2026 financial results on February 5. This disclosure is anticipated to provide stakeholders with further insights into the company’s capital deployment strategies and integration plans following the acquisition.
In the equity markets, shares of Haemonetics closed at $84.04, marking a 1.25% gain on the previous trading session. The stock is nearing its 52-week peak price of $87.32, indicating positive investor sentiment possibly influenced by the latest corporate developments.
Key Points:
- Haemonetics plans to acquire Vivasure Medical, expanding its structural heart and endovascular device portfolio.
- The acquisition focuses on Vivasure’s PerQseal Elite system, a bioabsorbable, sutureless large-bore vascular closure device supporting sizes up to 26F.
- Vivasure’s PerQseal Elite holds CE Mark approval in Europe and has submitted a U.S. FDA Premarket Approval application for arterial use.
- The transaction includes an upfront payment of approximately $117 million and up to $100 million in milestone payments, financed through Haemonetics’ cash reserves.
Risks and Uncertainties:
- Final regulatory approval from the U.S. FDA for the arterial version of PerQseal Elite is pending and subject to review outcomes.
- Achievement of milestone payments depends on future sales growth and operational benchmarks, which may be influenced by market conditions.
- Integration challenges of Vivasure’s technology and operations into Haemonetics’ existing business could impact anticipated synergies and timelines.
- Market acceptance and competitive dynamics within the large-bore vascular closure device segment remain variable and could affect revenue projections.
Disclosure: The terms of the acquisition and financial details have been released as per Haemonetics Corporation's public statements. Investors are advised to await the company’s forthcoming quarterly results for further updates on the acquisition integration and financial impact.